Responses
Immune cell therapies and immune cell engineering
Original research
Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope
Compose a Response to This Article
Other responses
No responses have been published for this article.